Clinical trials and equitable care pathways are needed to build on early evidence of benefit Substance use disorders (SUDs) are common and burdensome for patients, families, and health systems,12 yet ...

Novo Nordisk (NVO) plans to run studies on how its GLP-1 class of weight loss/diabetes drug can help people deal with addiction, Martin Holst Lange, the Danish pharma’s head of development, told an ...

A patient of mine, a veteran who had tried to quit smoking for over a decade, told me that after he started a GLP-1 drug for his diabetes, he lost interest in cigarettes. He didn’t use a patch. He ...

A $350 genetic test developed by researchers at Mayo Clinic in Rochester, Minn., and subsequently licensed to Phenomic Sciences, seeks to assign risk scores to patients regarding their likelihood of ...

Wegovy and Zepbound are two of the hottest GLP-1 drugs available on the market right now. The field, however, could become more crowded as more companies develop rival treatments. MariTide is a name ...

As GLP-1 drugs like Eli Lilly’s Mounjaro and Novo Nordisk’s Ozempic and Wegovy have spent the last couple of years skyrocketing in popularity—with no signs of slowing down—it was perhaps only a matter ...

A Stanford study shows simple digital prompts can motivate people taking GLP-1 medications to make lifestyle changes. It's a simple premise: What if something as small as a digital nudge could put ...

Phenomix's MyPhenome test continues to demonstrate predictive accuracy in identifying which patients are most likely to respond to GLP-1 therapies such as semaglutide. Studies presented at Obesity ...

A November 2025 Kaiser Family Foundation poll found that 1 in 8 U.S. adults have tried a GLP-1 medication for weight loss, diabetes or another condition. And we expect that number to rise now that one ...